Log in

NASDAQ:EGRXEagle Pharmaceuticals Competitors & Alternatives

$48.45
+1.23 (+2.60 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$46.84
Now: $48.45
$48.91
50-Day Range
$43.44
MA: $48.70
$53.61
52-Week Range
$33.80
Now: $48.45
$64.94
Volume136,800 shs
Average Volume194,266 shs
Market Capitalization$663.28 million
P/E Ratio285.02
Dividend YieldN/A
Beta1.02

Competitors

Eagle Pharmaceuticals (NASDAQ:EGRX) Vs. AMRN, KRTX, TARO, PCRX, APLS, and SAGE

Should you be buying EGRX stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Eagle Pharmaceuticals, including Amarin (AMRN), Karuna Therapeutics (KRTX), Taro Pharmaceutical Industries (TARO), Pacira Biosciences (PCRX), Apellis Pharmaceuticals (APLS), and SAGE Therapeutics (SAGE).

Eagle Pharmaceuticals (NASDAQ:EGRX) and Amarin (NASDAQ:AMRN) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, valuation, profitability, analyst recommendations, dividends, earnings and institutional ownership.

Earnings and Valuation

This table compares Eagle Pharmaceuticals and Amarin's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eagle Pharmaceuticals$195.89 million3.39$14.31 million$1.3835.11
Amarin$429.76 million6.03$-22,650,000.00($0.07)-96.00

Eagle Pharmaceuticals has higher earnings, but lower revenue than Amarin. Amarin is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

96.0% of Eagle Pharmaceuticals shares are held by institutional investors. Comparatively, 44.4% of Amarin shares are held by institutional investors. 21.1% of Eagle Pharmaceuticals shares are held by company insiders. Comparatively, 2.8% of Amarin shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Risk and Volatility

Eagle Pharmaceuticals has a beta of 1.02, indicating that its share price is 2% more volatile than the S&P 500. Comparatively, Amarin has a beta of 2.72, indicating that its share price is 172% more volatile than the S&P 500.

Profitability

This table compares Eagle Pharmaceuticals and Amarin's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Eagle Pharmaceuticals1.29%8.11%5.07%
Amarin-3.67%-4.05%-2.45%

Analyst Recommendations

This is a summary of current ratings and price targets for Eagle Pharmaceuticals and Amarin, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Eagle Pharmaceuticals01102.50
Amarin05802.62

Eagle Pharmaceuticals presently has a consensus price target of $52.50, indicating a potential upside of 8.36%. Amarin has a consensus price target of $17.2308, indicating a potential upside of 156.41%. Given Amarin's stronger consensus rating and higher probable upside, analysts clearly believe Amarin is more favorable than Eagle Pharmaceuticals.

Summary

Eagle Pharmaceuticals beats Amarin on 8 of the 14 factors compared between the two stocks.

Eagle Pharmaceuticals (NASDAQ:EGRX) and Karuna Therapeutics (NASDAQ:KRTX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

Analyst Ratings

This is a breakdown of current ratings for Eagle Pharmaceuticals and Karuna Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Eagle Pharmaceuticals01102.50
Karuna Therapeutics001103.00

Eagle Pharmaceuticals presently has a consensus price target of $52.50, indicating a potential upside of 8.36%. Karuna Therapeutics has a consensus price target of $117.7273, indicating a potential upside of 20.35%. Given Karuna Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Karuna Therapeutics is more favorable than Eagle Pharmaceuticals.

Insider & Institutional Ownership

96.0% of Eagle Pharmaceuticals shares are owned by institutional investors. Comparatively, 63.9% of Karuna Therapeutics shares are owned by institutional investors. 21.1% of Eagle Pharmaceuticals shares are owned by insiders. Comparatively, 18.1% of Karuna Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Eagle Pharmaceuticals and Karuna Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Eagle Pharmaceuticals1.29%8.11%5.07%
Karuna TherapeuticsN/A-18.24%-15.83%

Valuation & Earnings

This table compares Eagle Pharmaceuticals and Karuna Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eagle Pharmaceuticals$195.89 million3.39$14.31 million$1.3835.11
Karuna TherapeuticsN/AN/A$-43,960,000.00($3.68)-26.58

Eagle Pharmaceuticals has higher revenue and earnings than Karuna Therapeutics. Karuna Therapeutics is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Eagle Pharmaceuticals beats Karuna Therapeutics on 9 of the 12 factors compared between the two stocks.

Eagle Pharmaceuticals (NASDAQ:EGRX) and Taro Pharmaceutical Industries (NYSE:TARO) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.

Profitability

This table compares Eagle Pharmaceuticals and Taro Pharmaceutical Industries' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Eagle Pharmaceuticals1.29%8.11%5.07%
Taro Pharmaceutical Industries37.88%11.94%10.79%

Insider and Institutional Ownership

96.0% of Eagle Pharmaceuticals shares are owned by institutional investors. Comparatively, 11.6% of Taro Pharmaceutical Industries shares are owned by institutional investors. 21.1% of Eagle Pharmaceuticals shares are owned by insiders. Comparatively, 13.8% of Taro Pharmaceutical Industries shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current recommendations and price targets for Eagle Pharmaceuticals and Taro Pharmaceutical Industries, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Eagle Pharmaceuticals01102.50
Taro Pharmaceutical Industries00103.00

Eagle Pharmaceuticals currently has a consensus price target of $52.50, indicating a potential upside of 8.36%. Taro Pharmaceutical Industries has a consensus price target of $96.00, indicating a potential upside of 47.40%. Given Taro Pharmaceutical Industries' stronger consensus rating and higher probable upside, analysts clearly believe Taro Pharmaceutical Industries is more favorable than Eagle Pharmaceuticals.

Earnings and Valuation

This table compares Eagle Pharmaceuticals and Taro Pharmaceutical Industries' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eagle Pharmaceuticals$195.89 million3.39$14.31 million$1.3835.11
Taro Pharmaceutical Industries$644.77 million3.86$244.24 million$6.3510.26

Taro Pharmaceutical Industries has higher revenue and earnings than Eagle Pharmaceuticals. Taro Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Eagle Pharmaceuticals has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500. Comparatively, Taro Pharmaceutical Industries has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500.

Summary

Taro Pharmaceutical Industries beats Eagle Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

Eagle Pharmaceuticals (NASDAQ:EGRX) and Pacira Biosciences (NASDAQ:PCRX) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, analyst recommendations, profitability, dividends and risk.

Valuation and Earnings

This table compares Eagle Pharmaceuticals and Pacira Biosciences' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eagle Pharmaceuticals$195.89 million3.39$14.31 million$1.3835.11
Pacira Biosciences$421.03 million5.75$-11,020,000.00$0.8666.88

Eagle Pharmaceuticals has higher earnings, but lower revenue than Pacira Biosciences. Eagle Pharmaceuticals is trading at a lower price-to-earnings ratio than Pacira Biosciences, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

96.0% of Eagle Pharmaceuticals shares are owned by institutional investors. 21.1% of Eagle Pharmaceuticals shares are owned by insiders. Comparatively, 5.8% of Pacira Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current recommendations and price targets for Eagle Pharmaceuticals and Pacira Biosciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Eagle Pharmaceuticals01102.50
Pacira Biosciences051002.67

Eagle Pharmaceuticals currently has a consensus target price of $52.50, suggesting a potential upside of 8.36%. Pacira Biosciences has a consensus target price of $58.7857, suggesting a potential upside of 2.20%. Given Eagle Pharmaceuticals' higher possible upside, equities analysts clearly believe Eagle Pharmaceuticals is more favorable than Pacira Biosciences.

Risk and Volatility

Eagle Pharmaceuticals has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500. Comparatively, Pacira Biosciences has a beta of 1.31, suggesting that its share price is 31% more volatile than the S&P 500.

Profitability

This table compares Eagle Pharmaceuticals and Pacira Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Eagle Pharmaceuticals1.29%8.11%5.07%
Pacira Biosciences-0.02%13.89%6.06%

Eagle Pharmaceuticals (NASDAQ:EGRX) and Apellis Pharmaceuticals (NASDAQ:APLS) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation and risk.

Risk and Volatility

Eagle Pharmaceuticals has a beta of 1.02, indicating that its share price is 2% more volatile than the S&P 500. Comparatively, Apellis Pharmaceuticals has a beta of 1.26, indicating that its share price is 26% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and price targets for Eagle Pharmaceuticals and Apellis Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Eagle Pharmaceuticals01102.50
Apellis Pharmaceuticals05812.71

Eagle Pharmaceuticals presently has a consensus price target of $52.50, indicating a potential upside of 8.36%. Apellis Pharmaceuticals has a consensus price target of $51.00, indicating a potential upside of 57.16%. Given Apellis Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Apellis Pharmaceuticals is more favorable than Eagle Pharmaceuticals.

Valuation & Earnings

This table compares Eagle Pharmaceuticals and Apellis Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eagle Pharmaceuticals$195.89 million3.39$14.31 million$1.3835.11
Apellis PharmaceuticalsN/AN/A$-304,710,000.00($4.64)-6.99

Eagle Pharmaceuticals has higher revenue and earnings than Apellis Pharmaceuticals. Apellis Pharmaceuticals is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

96.0% of Eagle Pharmaceuticals shares are owned by institutional investors. Comparatively, 72.6% of Apellis Pharmaceuticals shares are owned by institutional investors. 21.1% of Eagle Pharmaceuticals shares are owned by insiders. Comparatively, 9.5% of Apellis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Eagle Pharmaceuticals and Apellis Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Eagle Pharmaceuticals1.29%8.11%5.07%
Apellis PharmaceuticalsN/A-276.49%-87.92%

Summary

Eagle Pharmaceuticals beats Apellis Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

SAGE Therapeutics (NASDAQ:SAGE) and Eagle Pharmaceuticals (NASDAQ:EGRX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent ratings for SAGE Therapeutics and Eagle Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
SAGE Therapeutics071102.61
Eagle Pharmaceuticals01102.50

SAGE Therapeutics presently has a consensus target price of $82.1111, indicating a potential upside of 91.31%. Eagle Pharmaceuticals has a consensus target price of $52.50, indicating a potential upside of 8.36%. Given SAGE Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe SAGE Therapeutics is more favorable than Eagle Pharmaceuticals.

Volatility and Risk

SAGE Therapeutics has a beta of 2.68, meaning that its share price is 168% more volatile than the S&P 500. Comparatively, Eagle Pharmaceuticals has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500.

Earnings & Valuation

This table compares SAGE Therapeutics and Eagle Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SAGE Therapeutics$6.87 million324.37$-680,240,000.00($13.38)-3.21
Eagle Pharmaceuticals$195.89 million3.39$14.31 million$1.3835.11

Eagle Pharmaceuticals has higher revenue and earnings than SAGE Therapeutics. SAGE Therapeutics is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares SAGE Therapeutics and Eagle Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SAGE Therapeutics-7,406.75%-63.13%-56.60%
Eagle Pharmaceuticals1.29%8.11%5.07%

Institutional and Insider Ownership

96.0% of Eagle Pharmaceuticals shares are owned by institutional investors. 4.8% of SAGE Therapeutics shares are owned by insiders. Comparatively, 21.1% of Eagle Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Eagle Pharmaceuticals beats SAGE Therapeutics on 9 of the 14 factors compared between the two stocks.

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Amarin logo
AMRN
Amarin
1.8$6.72+1.2%$2.56 billion$429.76 million-112.00
KRTX
Karuna Therapeutics
1.5$97.82+1.2%$2.56 billionN/A-0.67Insider Selling
Increase in Short Interest
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.4$65.13+0.0%$2.49 billion$644.77 million10.24Decrease in Short Interest
Pacira Biosciences logo
PCRX
Pacira Biosciences
1.4$57.52+1.7%$2.42 billion$421.03 million-2,874.56Analyst Upgrade
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.7$32.45+2.2%$2.40 billionN/A-5.17Increase in Short Interest
SAGE Therapeutics logo
SAGE
SAGE Therapeutics
1.6$42.92+2.9%$2.29 billion$6.87 million-3.45
IGMS
IGM Biosciences
1.5$71.65+0.7%$2.19 billionN/A-14.93Analyst Downgrade
TPTX
Turning Point Therapeutics
1.6$60.32+4.1%$2.17 billionN/A-16.76Analyst Report
Analyst Revision
Heavy News Reporting
Uniqure logo
QURE
Uniqure
1.7$47.66+1.8%$2.11 billion$7.28 million-15.83Analyst Downgrade
Principia Biopharma logo
PRNB
Principia Biopharma
1.4$64.03+7.9%$1.95 billion$35.16 million-26.24
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.0$16.75+0.5%$1.92 billion$306.49 million19.03
Eidos Therapeutics logo
EIDX
Eidos Therapeutics
1.1$48.82+0.9%$1.88 billion$26.69 million-36.98Analyst Upgrade
Insider Selling
Heavy News Reporting
Xencor logo
XNCR
Xencor
1.6$31.95+3.1%$1.88 billion$156.70 million-29.86Analyst Report
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
1.7$25.39+1.0%$1.88 billion$23.90 million-15.02Insider Selling
Decrease in Short Interest
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.4$112.21+0.2%$1.80 billion$120.28 million-32.62Analyst Downgrade
Unusual Options Activity
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.8$35.61+1.8%$1.79 billion$963.01 million12.81
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.8$14.88+2.5%$1.72 billion$320,000.00-11.36Analyst Downgrade
Zymeworks logo
ZYME
Zymeworks
1.7$33.19+5.7%$1.70 billion$29.54 million-8.53Analyst Report
Unusual Options Activity
Heavy News Reporting
Myovant Sciences logo
MYOV
Myovant Sciences
1.9$18.70+3.4%$1.68 billionN/A-5.55Analyst Report
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.8$103.91+3.6%$1.66 billionN/A-15.26Analyst Downgrade
Y-mAbs Therapeutics logo
YMAB
Y-mAbs Therapeutics
1.7$39.92+1.2%$1.66 billionN/A-16.03Analyst Downgrade
Heavy News Reporting
IMAB
I-Mab
1.2$29.50+2.7%$1.64 billion$4.31 million-1.02Lockup Expiration
Heavy News Reporting
Akebia Therapeutics logo
AKBA
Akebia Therapeutics
1.7$11.98+4.3%$1.63 billion$335 million-5.42Analyst Upgrade
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.5$24.43+2.5%$1.62 billion$60,000.00-8.79Analyst Downgrade
Unusual Options Activity
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.4$9.86+1.3%$1.57 billion$428.41 million18.60Analyst Downgrade
Cytokinetics logo
CYTK
Cytokinetics
1.6$25.50+2.4%$1.55 billion$26.87 million-11.38Analyst Upgrade
Insider Selling
Decrease in Short Interest
Heavy News Reporting
Epizyme logo
EPZM
Epizyme
1.6$15.16+0.1%$1.53 billion$23.80 million-7.47Analyst Downgrade
Zogenix logo
ZGNX
Zogenix
2.0$27.24+2.1%$1.52 billion$3.65 million-2.89Analyst Downgrade
Mersana Therapeutics logo
MRSN
Mersana Therapeutics
1.4$21.57+4.7%$1.51 billion$42.12 million-15.41Analyst Downgrade
MacroGenics logo
MGNX
MacroGenics
1.3$30.52+0.5%$1.51 billion$64.19 million-9.88Increase in Short Interest
Heavy News Reporting
ZNTL
Passage Bio
1.1$41.13+3.4%$1.47 billionN/A0.00Heavy News Reporting
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.3$25.34+2.9%$1.45 billion$410,000.00-6.40Analyst Upgrade
Heavy News Reporting
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
1.8$43.86+0.4%$1.44 billion$252 million-4.09
Esperion Therapeutics logo
ESPR
Esperion Therapeutics
1.4$51.70+2.0%$1.43 billion$148.36 million-5.37Increase in Short Interest
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.6$15.76+0.7%$1.42 billion$145.97 million-6.94
ZEALAND PHARMA/S logo
ZEAL
ZEALAND PHARMA/S
0.8$36.60+1.0%$1.42 billion$6.20 million-13.56
Portola Pharmaceuticals logo
PTLA
Portola Pharmaceuticals
1.5$18.03+0.0%$1.42 billion$116.64 million-4.78
Karyopharm Therapeutics logo
KPTI
Karyopharm Therapeutics
1.8$19.17+1.7%$1.38 billion$40.89 million-6.57
Innoviva logo
INVA
Innoviva
0.9$13.46+0.9%$1.38 billion$261.02 million7.87Analyst Downgrade
Kiniksa Pharmaceuticals logo
KNSA
Kiniksa Pharmaceuticals
1.4$22.25+3.6%$1.37 billionN/A-9.98
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.5$21.62+0.9%$1.35 billion$73.41 million-4.98Analyst Report
Increase in Short Interest
Akcea Therapeutics logo
AKCA
Akcea Therapeutics
1.2$13.29+4.5%$1.34 billion$488.54 million-44.30Analyst Downgrade
ARVN
Arvinas
1.6$34.22+0.8%$1.34 billion$42.98 million-15.48Analyst Downgrade
Increase in Short Interest
Tricida logo
TCDA
Tricida
2.0$26.00+2.1%$1.33 billionN/A-6.05Analyst Downgrade
Increase in Short Interest
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.8$23.68+3.1%$1.31 billionN/A-14.80
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
1.8$4.36+3.4%$1.31 billion$1.63 billion-2.71Analyst Downgrade
Heavy News Reporting
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.8$23.84+1.9%$1.25 billion$392.76 million10.99Analyst Downgrade
Constellation Pharmaceuticals logo
CNST
Constellation Pharmaceuticals
1.4$29.53+1.4%$1.24 billionN/A-10.11Analyst Downgrade
Odonate Therapeutics logo
ODT
Odonate Therapeutics
1.0$38.70+0.3%$1.24 billionN/A-9.85Analyst Downgrade
Arcus Biosciences logo
RCUS
Arcus Biosciences
1.7$25.47+0.7%$1.17 billion$15 million-11.79Increase in Short Interest
This page was last updated on 7/11/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.